CVS HEALTH (CVS) DIvidends Date & History

Key Takeaways

• CVS pays a quarterly dividend of $0.665 per share, or $2.66 annually, for a yield of roughly 2.8%.
• The dividend is comfortably covered by free cash flow, even though the payout ratio looks elevated on recent earnings.
• Dividend growth has paused — the last increase was a roughly 10% raise announced in late 2023, with the payout held flat since early 2024.
• CVS's yield sits above most managed-care peers, including UnitedHealth Group and Cigna.
• The stock is best suited to income-oriented investors who prioritize a stable yield over rapid payout growth.

Dividend Overview

CVS Health Corporation, one of the largest integrated healthcare and retail pharmacy companies in the United States, has maintained a consistent dividend policy for decades. The company currently pays $0.665 per share each quarter, which works out to an annual dividend of $2.66 per share. Based on recent share prices, that translates to a dividend yield of approximately 2.8%, a level that is above the broader healthcare sector average.

Dividends are distributed on a quarterly schedule, and the company has a long track record of returning capital to shareholders. With its dividend growth now effectively paused, CVS is best characterized not as a high-yield or fast-growing dividend stock, but as a large-cap healthcare payer offering a stable, above-average yield backed by substantial cash generation.

Dividend History and Growth

CVS has paid dividends since 1997 and raised them nearly every year for more than two decades, building a reputation as a reliable income payer. Over the past five years, the dividend has grown at a compound annual growth rate (CAGR, the average yearly growth over a set period) of roughly 5.9%.

However, that growth momentum has recently stalled. The company's last increase was a roughly 10% raise, announced in December 2023, which lifted the quarterly payment from $0.605 to $0.665 per share. Since then, management has held the dividend flat through 2024 and into 2026, reflecting pressure on earnings tied to elevated medical costs in its health insurance segment and the ongoing integration of its Aetna business. For dividend growth investors, this pause is a meaningful shift from the company's historically consistent pattern of annual increases.

Dividend Sustainability and Payout Ratio

Assessing CVS's dividend sustainability requires looking beyond a single metric. On a trailing generally accepted accounting principles (GAAP) basis, the payout ratio has appeared stretched — sometimes exceeding 100% of earnings per share (EPS, the portion of profit allocated to each share) — because recent quarters have been weighed down by one-time and non-cash charges. Adjusted for those items, the payout ratio sits closer to roughly 70% of earnings.

More importantly, the dividend is well supported by cash generation. The company's dividend consumes only a minority of its free cash flow (FCF, the cash left after capital spending), with the cash-based payout ratio estimated at roughly 46% or lower in some periods. This is a key point: even with elevated medical costs and high debt levels following the Aetna acquisition, CVS's enormous cash flow from its pharmacy and healthcare services businesses provides a cushion that keeps the dividend viable, even if earnings remain volatile.

Dividend Compared to Industry Peers

Within the managed-care and pharmacy space, CVS offers a comparatively attractive yield. Rival UnitedHealth Group yields roughly 1.4%, while Cigna yields around 2%, placing CVS's approximate 2.8% yield meaningfully above both. The contrast is even sharper against Walgreens Boots Alliance, which suspended its dividend entirely in early 2025 amid financial restructuring.

That said, CVS's yield is not the highest in the sector, and its paused dividend growth means it does not currently offer the rising-payout profile that some peers maintain. Investors effectively receive a mid-single-digit income stream today in exchange for accepting that payout increases may remain on hold until earnings normalize.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is particularly useful for identifying dividend stocks, income-focused investments, trending stocks, breakout candidates, and emerging market opportunities far more efficiently than manual screening. Explore the AI Screener to build a watchlist tailored to your investment criteria.

Is This Stock Attractive for Dividend Investors?

CVS is likely to appeal most to income-oriented and long-term investors who value a stable, above-average yield and do not require rapid annual dividend increases. Its roughly 2.8% yield, backed by strong free cash flow, makes it a reasonable candidate for portfolios focused on current income, particularly given that its payout is higher than several large healthcare peers.

For strict dividend growth investors, however, the flat payout since early 2024 is a drawback, as it interrupts a previously reliable pattern of increases. Conservative investors should also weigh the company's elevated debt and the ongoing cost pressures in its insurance segment, which could keep earnings — and therefore future dividend growth — under pressure in the near term. Overall, CVS presents a balanced profile: an attractive yield today, with meaningful questions about how quickly the payout will resume growing.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations